文献速递肝肾功能剂量调整药物相互作用

利奥西呱的临床药代动力学与药效学特征

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.
PubMed 文献 · Clin Pharmacokinet · 2018-01-01

利奥西呱是口服可溶性鸟苷酸环化酶刺激剂,靶向NO-sGC-cGMP通路,兼具直接刺激sGC和增加sGC对NO敏感性的双重作用机制。其生物利用度94.3%,半衰期患者约12小时、健康人约7小时,经肾(33-45%)和胆道(48-59%)排泄。在PAH或CTEPH患者中暴露个体间变异60%、个体内变异30%,需个体化剂量调整。

要点

  • 利奥西呱生物利用度94.3%,可整片或压碎服用,不受进食影响。
  • 中重度肝损或轻至重度肾损患者需谨慎调整剂量,重度肝损无数据。
  • 治疗药物相互作用风险低,因经多种CYP酶清除且不影响主要CYP和转运体。

核心结论

  • 利奥西呱药代动力学特征支持在PAH和CTEPH患者中采用个体化剂量调整方案。

研究设计与样本

  • 本文为利奥西呱的临床药代动力学与药效学特征综述,涵盖吸收、分布、代谢、排泄及药物相互作用。

主要发现

  • 利奥西呱快速吸收,生物利用度94.3%,患者半衰期约12小时,健康人约7小时。
  • PAH或CTEPH患者中利奥西呱暴露个体间变异60%、个体内变异30%。
  • 利奥西呱经肾(33-45%)和胆道(48-59%)双途径排泄。
  • III期群体PK/PD分析显示PAH或CTEPH患者血流动力学反应与利奥西呱暴露相关。

关键数值与推荐

  • 中重度肝损或轻至重度肾损患者应特别谨慎调整剂量,重度肝损无数据。
  • 利奥西呱因经多种CYP酶清除且治疗浓度下不影响主要CYP和转运体,临床相关药物相互作用风险低。

临床怎么用

  • PAH和CTEPH患者起始治疗时应按个体剂量调整方案给药。
  • 中度肝损或轻至重度肾损患者需谨慎调整利奥西呱剂量。

局限性

  • 重度肝损患者无药代动力学数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oral riociguat is a soluble guanylate cyclase (sGC) stimulator that targets the nitric oxide (NO)-sGC-cyclic guanosine monophosphate pathway with a dual mode of action: directly by stimulating sGC, and indirectly by increasing the sensitivity of sGC to NO. It is rapidly absorbed, displays almost complete bioavailability (94.3%), and can be taken with or without food and as crushed or whole tablets. Riociguat exposure shows pronounced interindividual (60%) and low intraindividual (30%) variability in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), and is therefore administered using an individual dose-adjustment scheme at treatment initiation. The half-life of riociguat is approximately 12 h in patients and approximately 7 h in healthy individuals. Riociguat and its metabolites are excreted via both renal (33-45%) and biliary routes (48-59%), and dose adjustment should be performed with particular care in patients with moderate hepatic impairment or mild to severe renal impairment (no data exist for patients with severe hepatic impairment). The pharmacodynamic effects of riociguat reflect the action of a vasodilatory agent, and the hemodynamic response to riociguat correlated with riociguat exposure in patients with PAH or CTEPH in phase III population pharmacokinetic/pharmacodynamic analyses. Riociguat has a low risk of clinically relevant drug interactions due to its clearance by multiple cytochrome P450 (CYP) enzymes and its lack of effect on major CYP isoforms and transporter proteins at therapeutic levels. Riociguat has been approved for the treatment of PAH and CTEPH that is inoperable or persistent/recurrent after surgical treatment.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Frey R, Becker C, Saleh S, et al. Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat. Clin Pharmacokinet. 2018. PMID: 29086344. doi:10.1007/s40262-017-0604-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。